Relay Therapeutics Inc. (NASDAQ:RLAY) saw an upside of 2.32% to close Friday at $10.59 after adding $0.24 on the day. The 5-day average trading volume is 740,220 shares of the company’s common stock. It has gained $11.23 in the past week and touched a new high 1 time within the past 5 days. An average of 796,520 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,087,276.
RLAY’s 1-month performance is -12.70% or -$1.52 on its low of $10.19 reached on 08/18/23. The company’s shares have touched a 52-week low of $9.67 and high of $33.06, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, RLAY has lost -29.12% or -$4.35 and has reached a new high 9 times. However, the current price is down -67.97% from the 52-week high price.
Insider Transactions
RLAY stock investors last saw insider trading activity on Jul 28.Bergstrom Donald A (President, R&D) most recently sold 2,683 shares at $11.80 per share on Jul 28. This transaction cost the insider $31,659. Chief Financial Officer, Catinazzo Thomas, sold 1,693 shares at a price of $11.80 on Jul 28. Then, on Jul 28, Chief Legal Officer Adams Brian sold 1,628 shares at a price of $11.80 per share. This transaction amounted to $19,210.
Valuation Metrics
RLAY stock has a beta of 1.39. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1398.59 while the price-to-book (PB) in the most recent quarter is 1.59.
Relay Therapeutics Inc.’s quick ratio for the period ended June 29 was 12.40, with the current ratio over the same period at 12.40. The trailing 12-month EBITDA margin is -22217.38%. The firm’s gross profit as reported stood at $300.66 million against revenue of $1.38 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 22.05% to -$98.51 million, while revenue of -$94.24 million was 4.33% off the previous quarter. Analysts expected RLAY to announce -$0.82 per share in earnings in its latest quarter, but it posted -$0.81, representing a 1.20% surprise. EBITDA for the quarter stood at more than -$106.92 million. RLAY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 151.9 million, with total debt at $55.71 million. Shareholders hold equity totaling $122.13 million.
Let’s look briefly at Relay Therapeutics Inc. (RLAY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 41.03% to suggest the stock is trending Neutral, with historical volatility in this time period at 55.65%.
The stock’s 5-day moving average is $10.63, reflecting a -1.30% or -$0.14 change from its current price. RLAY is currently trading -14.53% above its 20-day SMA, -31.59% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -9.02% and SMA200 by-52.34%.
Stochastic %K and %D was 10.91% and 14.47% and the average true range (ATR) pointed at 0.64. The RSI (14) points at 42.10%, while the 14-day stochastic is at 17.44% with the period’s ATR at 0.65. The stock’s 9-day MACD Oscillator is pointing at -0.33 and -0.48 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Relay Therapeutics Inc. (NASDAQ: RLAY), Jefferies upgraded it to a Hold rating. They previously had an Underperform rating on the stock. Analysts offering their rating for RLAY stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RLAY as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 12 have offered a “buy” rating.
What is RLAY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $15.00 and a high of $38.00, with their median price target at $29.00. Looking at these predictions, the average price target given by analysts is for Relay Therapeutics Inc. (RLAY) stock is $27.42.
